Bayer‘s Vitrakvi is a kinase inhibitor that is FDA indicated to treat adult and pediatric patients with solid tumors. Specifically, FDA indicates it for solid tumors with the following criteria: Presence of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation. Metastatic or where surgical resection is likely to result in severe morbidity.…